In this analysis, individuals with the CELF4 rs1786814 GG genotype, who received high dose of anthracyclines (>300 mg/m2) were at 10-fold higher risk of cardiomyopathy (p < 0.001) compared to those with the GA/AA genotype and low to moderate dose (<300 mg/m2). This evidence concerns the gene CELF4 and cardiomyopathy.